RACK1 (receptor for activated C-kinase 1), an anchoring protein that shuttles activated PKC to cellular membranes, plays an important role in PKC-mediated signal transduction pathways. A significant loss of RACK1 has been found in the brain of aging animals and Alzheimer's disease (AD) patients, which implicates the potential involvement of RACK1 in altered PKC activation associated with dementia. Our previous studies have demonstrated that GABAergic inhibition in prefrontal cortex, which is important for cognitive processes like "working memory", is regulated by muscarinic receptors via a PKC-dependent mechanism, and this effect is impaired by ␤-amyloid peptide (A␤). In this study, we found that A␤ oligomers decreased RACK1 distribution in the membrane fraction of cortical neurons. Moreover, overexpression of RACK1 rescued the effect of muscarinic receptors on GABAergic transmission in A␤-treated cortical cultures in vitro and A␤-injected cortical neurons in vivo. These results suggest that the A␤-induced loss of RACK1 distribution in the cell membrane may underlie the A␤ impairment of muscarinic regulation of PKC and GABAergic transmission. Thus, RACK1 provides a potential therapeutic target that can restore some of the impaired cellular processes by A␤.
RACK1 is a member of the tryptophan-aspartate (WD) repeat family known for its propeller-like structure (Neer et al., 1994) . Like many other WD domain proteins, RACK1 plays different roles upon binding to different partner proteins. RACK1 was first characterized as an intracellular receptor that binds activated PKC and is involved in activation-induced translocation of PKC to the membrane (Mochly-Rosen et al., 1991) . RACK1 is present in the particulate fraction when binding activated PKC isozymes (Ron et al., 1994) , bringing the signaling enzyme to the appropriate location, in close proximity with its substrate proteins (Jaken and Parker, 2000) . In addition to PKC, RACK1 interacts with diverse proteins, including the small subunit of hetero-trimeric G protein G␤ (Dell et al., 2002) , IP 3 receptors (Patterson et al., 2004) , the neuronal transport protein Dynamin 1 (Rodriguez et al., 1999) , GABA A receptors (Brandon et al., 1999) , and NMDA receptors (Yaka et al., 2002) . Thus, RACK1 has been implicated in multiple key neuronal functions, such as intracellular Ca 2+ regulation, protein trafficking, synaptic transmission and plasticity (Sklan et al., 2006) .
Changes in RACK1 levels have been found in a number of brain pathologies and during aging. For example, several reports show that RACK1 is decreased by ∼50% in membrane fractions of aging rat brains (Pascale et al., 1996; Battaini et al., 1997; McCahill et al., 2002) . Reports on RACK1 changes in postmortem brains of AD patients are less consistent, with a reduction found in some studies (Battaini et al., 1999) , but not others (Shimohama et al., 1998) . Moreover, RACK1 levels are significantly decreased in the cortex of Down syndrome patients (Peyrl et al., 2002) , all of who develop early onset AD. It suggests that loss of RACK1 may contribute to decreased PKC activity in the aging brain or AD.
The accumulation of ␤-amyloid (A␤), a peptide generated from the amyloid precursor protein (APP), is one of the hallmarks of AD (Tanzi and Bertram, 2001; Selkoe and Schenk, 2003) . Emerging evidence suggests that A␤ causes "synaptic failure" before the formation of senile plaques and the occurrence of neuron death (Selkoe, 2002) . Our previous studies have found that A␤ impairs PKC-dependent regulation of synaptic functions by muscarinic acetylcholine receptors (mAChR) and metabotropic glutamate receptors (mGluR) in cortical neurons Tyszkiewicz and Yan, 2005) . However, it is unclear about the mechanism underlying this action of A␤. In this study, we provide evidence showing that the A␤-induced impairment of PKC activation and synaptic regulation may be attributed to RACK1 deficit.
Materials and methods

Aβ oligomer preparation
Oligomeric A␤ was prepared as what was previously described (Dahlgren et al., 2002; Gu et al., 2009) . Briefly, A␤ 42 peptide (Sigma) was dissolved in hexafluoroisopropanol (HFIP) to 1 mM. HFIP was then removed under vacuum. The remaining peptide was then dissolved in DMSO to 5 mM and diluted in PBS to 100 M. The oligermeric A␤ was formed by incubating at 4 • C for 24 h.
Primary neuronal culture
All experiments were performed with the approval of the State University of Buffalo Animal Care Committee. Rat cortical cultures were prepared as previously described . Brief, frontal cortex was dissected from embryonic day 18 embryos, and cells were dissociated using trypsin and triturated through a Pasteur pipette. Neurons were plated on poly-l-lysine coated coverslips in Dulbecco's modified Eagle's medium with 10% fetal calf serum at a density of 1 × 10 5 cells/cm 2 . When neurons attached to the coverslip within 24 h, the medium was changed to neurobasal medium with B27 supplement (Invitrogen, Carlsbad, CA). Neurons were maintained for 2-3 weeks.
Whole-cell recordings
Standard voltage-clamp techniques (Liu et al., 2006) were used for whole-cell recordings of spontaneous IPSC in cultured neurons. The external solution contained (mM):
127 NaCl, 5 KCl, 2 MgCl 2 , 2 CaCl 2 , 10 HEPES, 12 glucose, pH 7.3-7.4, 300-305 mOsm. The internal solution contained (in mM): 100 CsCl, 30 N-methyl-d-glucamine, 10 HEPES, 1 MgCl 2 , 4 NaCl, 5 EGTA, 0.1 QX314, 12 phosphocreatine, 2 MgATP, 0.2 Na 3 GTP, 0.1 leupeptin, pH 7.2-7.3, 265-270 mOsm. The AMPA/KA receptor antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX, 10 M) and NMDA receptor antagonist d-aminophosphonovalerate (APV, 25 M) were present in the external solution throughout the recording. Cells were held at −70 mV.
Whole-cell voltage-clamp techniques were used for recordings of slices from young adult (3-4 weeks postnatal) Sprague-Dawley rats . The brain slice (300 m) was submerged in oxygenated artificial cerebrospinal fluid (ACSF) containing CNQX (10 M) and APV (25 M). The internal solution was the same as that used for culture recordings. Cells were visualized with a waterimmersion lens and illuminated with near-IR light. Tight seals (2-10 G ) from visualized pyramidal neurons were obtained by applying negative pressure. The membrane was disrupted with additional suction and the whole-cell configuration was obtained. The access resistances ranged from 13 to 18 M and were compensated 50-70%. The recording of spontaneous IPSC were performed on neurons (held at −70 mV) using a Multiclamp 700 A amplifier (Axon Instruments).
Subcellular fractionation of proteins and Western blot analysis
Cultured cortical neurons (DIV 11-16) were treated with A␤ oligomer (1 M) for 48-72 h. After treatment, cultured neurons were homogenized on ice with the lysis buffer (0.3 M sucrose, 0.15 M NaCl, 20 mM Tris-HCl (pH 7.4), 2 mM EDTA, 0.3 mM PMSF, and 10 g/ml leupeptin). Homogenates were centrifuged at 1000 × g for 10 min at 4 • C, and supernatant fractions were collected for ultracentrifugation. Cytosol and membrane fractions were separated by ultracentrifugation at 100,000 × g for 90 min at 4 • C. The supernatant constituted the cytosol fraction, and the pellet was resuspended and homogenized in the above lysis buffer with 0.2% Triton X-100 added. This resuspended fraction represented the membrane fraction.
Samples were boiled in 2× SDS loading buffer for 5 min, loaded at 30 g of cytosol fractions and membrane fractions, separated on 10% SDS-polyacrylamide gel and transferred to nitrocellulose membranes. The blots were incubated with primary antibodies, including RACK1 (Santa Cruz), PKC (Santa Cruz), or actin (Santa Cruz). For detecting activated PKC, a phospho-PKC (pan) antibody (Cell Signal) that recognizes PKC␣, ␤I, ␤II, , , and ␦ isoforms only when phosphorylated at a carboxy-terminal residue homologous to Ser660 of PKC␤II was used in the Western blot analysis. The A␤ antibody (Chemicon, 6E10, 1:500) was used for detecting oligomeric A␤. After incubation with secondary antibodies conjugated with horseradish peroxidase (Amersham Biosciences), quantification was obtained from densitometric measurements of immunoreactive bands on films.
siRNA transfection
To knockdown RACK1, the target-specific 19-25 nt siRNA designed against rat RACK1 (Santa Cruz) was transfected into cultured cortical neurons (DIV 11-16) using Lipofectamine 2000 reagent as we described before (Gu et al., 2009 ). RACK1 siRNA (20 nM) was co-transfected with EGFP (0.5 g/ml). Cultures were recorded 2-3 days after transfection.
Construction of Sindbis viruses and in vivo infection
The cDNAs encoding GFP and GFP-RACK1 were subcloned to pSinRep5 vector (Invitrogen) according to the manufacturer's protocol. Recombinant GFP-pSinRep5 and GFP-RACK1-pSinRep5 were linearized with Not I. The DH26S plasmid was linearized using Xho I. The linearized templates were transcribed in vitro using mMessage Machine SP6 kit (Ambion) and the RNAs were electroporated into baby hamster kidney (BHK) cells. The extracellular medium containing the recombinant viruses was harvested after 24-48 h. The medium was concentrated on a discontinuous sucrose gradient (55% and 20% sucrose) using ultracentrifugation (160,000 × g, 90 min at 4 • C) (Hu et al., 2006) . Cultured cortical neurons (11-16 DIV) were infected by adding the viral suspension directly to the medium (10 l added to 100 l culture medium, 1 h later add 900 l new medium). After 24 h of infection, more than 80% of the neurons appeared GFP positive. Recordings were performed 2-3 days after infection. The virus did not cause apparent toxicity to cultured neurons at least 4 days after infection.
For viral expression in vivo (McCormack et al., 2006; Kopec et al., 2007) , rats (3-4 weeks old) were anesthetized by an i.p. injection of pentobarbital (50 mg/kg), and placed on a stereotaxic instrument. The viral suspension (0.5 l) and A␤ oligomer (100 M, 0.5 l) were mixed and injected with a Hamilton syringe (needle gauge 31) at a speed of ∼0.2 l/min, and the needle was kept in place for an additional 5 min. The virus and A␤ were delivered bilaterally to prefrontal cortex using the following coordinates (mm): AP 2.5, ML 0.75, and DV 3.5. After 48-72 h of injection, the slices from the infected brains were used for recording.
Statistics
Spontaneous synaptic events were analyzed with Mini Analysis Program (Synaptosoft, Leonia, NJ). Statistical comparisons of the amplitude and frequency of sIPSC were made using the Kolmogorov-Smirnov (K-S) test. ANOVA tests were performed to compare the differential degrees of current modulation between groups subjected to different treatments.
Results
Aβ treatment decreased RACK1, PKC and p-PKC in the membrane fraction of cortical cultures
Given the involvement of RACK1 in the activationinduced translocation of PKC to the membrane (MochlyRosen et al., 1991), we speculate that RACK1 is potentially involved in A␤-induced impairment of PKC activation. To test this, we measured the effect of A␤ on the distribution of RACK1 by treating cultured cortical neurons with oligomeric A␤ (1 M). As shown in the Western blot of oligomeric A␤ (Fig. 1A) , there were several bands of signals between 4 and 22 kDa, suggesting the presence of A␤ monomers, dimers, trimers and tetramer.
After ∼48 h of treatment with A␤ oligomer, neurons were homogenized, and the cytosol and membrane fraction were separated using ultracentrifugation. As shown in Fig. 1B , A␤ treatment did not alter endogenous RACK1 (33 kDa) in the cytosol fraction, but induced a marked reduction of RACK1 in the membrane fraction.
Since RACK1 is an anchoring protein that translocates activated PKC from the cytosol fraction to the membrane fraction (Mochly-Rosen et al., 1991; Ron et al., 1994) , we examined whether the A␤-induced reduction of RACK1 distribution at cellular membranes also affected translocation and activation of PKC. Because the catalytic competence of many PKC isozymes depends on autophosphorylation at the carboxyl terminus on a conserved residue (Behn-Krappa and Newton, 1999), a phosphospecific pan PKC antibody that detects PKC isoforms only when phosphorylated at this residue was used to detect activated PKC. As shown in Fig. 1B , A␤ treatment also decreased the distribution of PKC and p-PKC (activated) in the membrane fraction, but not in the cytosol fraction. Quantification data (Fig. 1C) show that RACK1 in the membrane fraction was decreased to 68.7 ± 4.1% of control (n = 6, p < 0.01, ANOVA) by A␤ treatment. Similarly, PKC and p-PKC in the membrane fraction were reduced to 66.8 ± 3.5% and 70.5 ± 5.7% of control (n = 6, p < 0.01, ANOVA), respectively, by A␤ treatment. No significant difference was found on cytosolic RACK1, PKC and p-PKC between control and A␤-treated neurons. These data indicate that oligomeric A␤ treatment reduces the level of RACK1, PKC and p-PKC at cellular membranes of cortical cultures.
To detect whether overexpression of RACK1 restores A␤-induced loss of PKC and p-PKC in the membrane fraction, we infected cortical cultures with GFP-RACK1 Sindbis virus. After 2 days of A␤-treatment, neurons were subjected to Western blot assays. As shown in Fig. 1B and C, the overexpression of recombinant GFP-RACK1 (60 kDa) was confirmed in RACK1-infected neurons. The level of PKC and p-PKC in the membrane fraction was elevated by RACK1 overexpression. After A␤ treatment, the membrane level of PKC and p-PKC in RACK1-infected neurons was similar to that in untreated neurons without infection (control), suggesting that the loss of PKC and p-PKC by A␤ is restored by RACK1 overexpression.
Overexpression of RACK1 rescued the muscarinic regulation of GABAergic transmission in Aβ-treated cortical cultures
Our previous study has shown that mAChR activation increases the amplitude of spontaneous inhibitory postsynaptic current (sIPSC) in cortical slices via a PKC-dependent mechanism, which was impaired by A␤ 25-35 treatment or in APP transgenic mice, probably due to the A␤-mediated interference of mAChR activation of PKC . Since A␤ treatment reduces the level of RACK1 and activated PKC at the membrane fraction of cortical cultures, we would like to know whether overexpression of RACK1 could rescue the effect of mAChRs on GABAergic transmission in A␤-treated neurons.
First, we examined the involvement of RACK1 in muscarinic regulation of GABAergic transmission. As shown in Fig. 2A -C, bath application of the mAChR agonist carbachol (20 M) caused a significant (p < 0.01, ANOVA) increase in the amplitude and frequency of sIPSC (amplitude: 63.2 ± 14.3%, frequency: 157.6 ± 33.3%, n = 20; Fig. 2G and H), consistent with our previous finding . To test the involvement of RACK1 in muscarinic regulation of sIPSC, we dialyzed neurons with a peptide derived from the sixth WD40 repeats of RACK1 (DGGDIINALCFSPNR) to inhibit PKC binding to RACK1 (Ron et al., 1994; Feng et al., 2001) . As shown in Fig. 2D -H, dialysis with the RACK1 peptide (40 M) significantly diminished the enhancing effect of carbachol on sIPSC amplitude (6.9 ± 8.8%, n = 17), while did not alter the effect of carbachol on sIPSC frequency (152.8 ± 19.5%, n = 17). On the other hand, dialysis with a scrambled control peptide (FDSRGIGPDINCANL) did not block the enhancing effect of carbachol on sIPSC amplitude or frequency ( Fig. 2G and H) . It suggests that muscarinic modulation of sIPSC amplitudes requires RACK1 to anchor activated PKC to the membrane of inhibitory synapses.
To confirm the specificity of PKC involvement, we also examined the potential role of several other molecules in muscarinic regulation of GABAergic transmission. Application of the acetylcholinesterase (AChE) inhibitor physostigmine (40 M) increased sIPSC (amplitude: 51.1 ± 9.3%, frequency: 148.5 ± 39.3%, n = 10), mimicking the effect of carbachol. Furthermore, the enhancing effect of carbachol on sIPSC was occluded by physostigmine ( Fig. 2G and H, amplitude: 5.91 ± 2.9%, frequency: 19.6 ± 16.8%, n = 10), suggesting its dependence on acetylcholine. On the other hand, the effect of carbachol was not significantly altered by the protein phosphatase inhibitor okadaic acid (OA, 1 M, amplitude: 71.6 ± 16.8%, frequency: 155.3 ± 34.5%, n = 10) or the PKA inhibitor H89 (10 M, amplitude: 58.7 ± 13.8%; frequency: 155.6 ± 30.6%, n = 10, Fig. 2G and H), which ruled out the involvement of these signaling molecules.
We further examined whether overexpression of RACK1 could restore the impaired muscarinic regulation of GABAergic transmission in A␤-treated neurons. We infected cortical cultures (DIV 11-16) with GFP or GFP-tagged RACK1 Sindbis viruses. Sindbis virus vector can infect neurons with high efficiency and has been widely applied in neuroscience research (Schlesinger and Dubensky, 1999; Maletic-Savatic et al., 1999; Ehrengruber et al., 1999) . After 2-3 days of infection, we stained neurons with MAP2, a dendritic marker, to examine their viability and morphological features. As shown in Fig. 3A and D, most MAP2-labeled neurons were also GFP positive, and they looked healthy, confirming the high infection efficiency and low neuronal toxicity. The expression pattern of GFP and GFP-RACK1 was different, with GFP showing even distribution throughout the neurons, while GFP-RACK1 displaying more punctuate pattern, especially in the dendrites.
During infection, cortical neurons were also treated with oligomeric A␤ (1 M). After 2-3 days of treatment, GFP+ neurons were subjected to recording. As shown in Fig. 3B and C, A␤ diminished the effect of carbachol on sIPSC amplitude in neurons overexpressing GFP (8.0 ± 10.6%, n = 15, Fig. 3H ). In contrast, overexpression of GFP-RACK1 rescued the enhancing effect of carbachol on sIPSC amplitude (Fig. 3E and F, 57 .8 ± 15.3%, n = 15, Fig. 3H ). Overexpression of RACK1 alone did not significantly alter the effect of carbachol on sIPSC amplitude (75.7 ± 15.7%, n = 8, Fig. 3H ). The effect of carbachol on sIPSC frequency, which is PKCindependent , was not altered by A␤ in neurons infected with GFP or GFP-RACK1 (Fig. 3I) . These data suggest that overexpressing RACK1 in vitro restores the A␤-induced loss of muscarinic effects on sIPSC amplitudes in cortical cultures.
To further confirm the role of RACK1 in carbachol regulation of GABAergic transmission, we performed cellular knockdown experiments by transfecting RACK1 siRNA to cortical cultures. The specific suppression of RACK1 expression in siRNA-transfected (GFP+) neurons is illustrated in Fig. 3G . Knockdown of RACK1 abolished the enhancing effect of carbachol on sIPSC amplitude (11.8 ± 12.5%, n = 8, Fig. 3H ), but not on sIPSC frequency (145.52 ± 2.7%, n = 8, Fig. 3I ). 
Injection of Aβ into animals impaired muscarinic regulation of GABAergic transmission, which was rescued by RACK1 expression in vivo
To confirm the in vitro results, we examined the impact of A␤ and RACK1 in vivo. Sindbis virus vector-based gene delivering enables rapid and efficient heterologous protein expression in neurons (McCormack et al., 2006; Kopec et al., 2007) , so we used it for transient RACK1 expression in vivo. Oligomeric A␤ (100 M) was delivered to rat frontal cortex via a stereotaxic injection. GFP or GFP-RACK1 Sindbis viruses were also injected simultaneously. As shown in Fig. 4A and C, after 2-3 days of infection, these viruses were efficiently expressed in neurons at the proximity of injected sites, and the GFP+ neurons showed normal morphology. In cortical pyramidal neurons without A␤ injection, application of carbachol (20 M) increased sIPSC amplitude by 71.7 ± 18.9% (n = 26, Fig. 4E ), consistent with our previous study . However, in GFP-infected cortical neurons from A␤-injected animals, the enhancing effect of carbachol on sIPSC amplitudes was largely abolished (Fig. 4B, 6 .3 ± 9.2%, n = 15, Fig. 4E ). Interestingly, in RACK1-infected cortical neurons from A␤-injected animals, the enhancing effect of carbachol on sIPSC amplitudes was restored (Fig. 4D, 65 .9 ± 16.7%, n = 13, Fig. 4E) . Again, the effect of carbachol on sIPSC frequency was not altered by A␤ injection (Fig. 4F) . These data indicate that oligomeric A␤ blocks the enhancement of carbachol on sIPSC amplitudes in rat cortical neurons in vivo, which is rescued by RACK1 expression.
Discussion
Cholinergic system is involved in many cognitive functions, such as attention (Voytko et al., 1994) , learning (Fine et al., 1997) and memory (Hasselmo et al., 1992) . Selective degeneration of cholinergic neurons in basal forebrain is a major feature of AD (Whitehouse et al., 1982; Selkoe, 2001) . The action of acetylcholine is mediated by muscarinic and nicotinic receptors. It has been reported that nicotinic receptors are significantly lost in cortical and hippocampal areas of AD brains (Perry et al., 1995) , whereas m1 muscarinic receptors are preserved in most AD patients (Araujo et al., 1988) . However, several studies indicate that the interaction between m1 muscarinic receptors and G proteins is affected in AD brains (Flynn et al., 1991; Cowburn et al., 1996) . So it is important to elucidate the downstream signaling pathway of muscarinic receptors in the normal condition and how it goes awry in the AD state.
Prefrontal cortex (PFC), which has long been implicated in cognitive processes (Dalley et al., 2004) , such as "working memory" (Goldman-Rakic, 1995) , is a major target area of the basal forebrain cholinergic system. The cholinergic innervation of PFC is critically involved in "working memory" (Dunnett et al., 1990; Broersen et al., 1995) , while the underlying mechanism is unclear. It has been suggested that "working memory" relies on GABAergic inhibition in PFC, which controls the timing of neuronal activity during cognitive operations (Constantinidis et al., 2002) . Our previous studies show that muscarinic receptors regulate PFC GABAergic transmission via a PKC-dependent mechanism (Ma et al., 2003) , and this effect is impaired in APP transgenic mice and A␤-treated slices . In this study, we demonstrate that the impairment is likely due to A␤-induced decrease of RACK1 distribution in the neuronal membrane.
RACK1 is a scaffold protein with complex functions because of its promiscuous and dynamic capacity to interact with multiple partners (Sklan et al., 2006) . PKC is the first identified RACK1 partner protein. PKC typically translocates to the membrane upon activation, however its residence on membranes is transient if not stabilized by interacting with RACK1 (Mochly-Rosen et al., 1991; Ron et al., 1995; McCahill et al., 2002) . PKC isozymes located at different subcellular compartments are differentially involved in distinct organ functions, such as the regulation of ion channels, neurotransmission, synaptic plasticity, learning and memory (Tanaka and Nishizuka, 1994) . The disparate functional effects of specific PKC isozymes can be determined by binding to RACKs (Sklan et al., 2006) . AD-related changes in the expression and activity of PKC isoforms have been investigated, with several reports indicating that PKC activities are reduced in AD brains (Cole et al., 1988; Wang et al., 1994; Matsushima et al., 1996) . There is also evidence indicating that the level of RACK1 is decreased in the membrane fraction of aging rat cortex (Battaini et al., 1997; Pascale et al., 1996) and aging rabbit hippocampus (Van der Zee et al., 2004) , as well as in both soluble and membrane fractions of AD brains (Battaini et al., 1999) . Accompanying to the reduced RACK1 is the impaired translocation of PKC from the cytosol to the plasma membrane (Battaini et al., 1997; Pascale et al., 1996; Van der Zee et al., 2004) . Consistent with these, we found that A␤ treatment reduces RACK1 levels in the membrane fraction of PFC neurons, with a concomitant decrease of total PKC and activated PKC levels in the membrane.
The A␤-induced loss of RACK1 membrane distribution could underlie the A␤-induced loss of m1/PKC regulation of GABA transmission in PFC. The best supporting evidence is the rescue experiments. We have shown that overexpression of RACK1 restores the muscarinic effect on GABA transmission in A␤-treated PFC neurons. This in vitro result is confirmed by using viral-based gene delivering in vivo. It suggests that RACK1 is a potential therapeutic target that can rescue some of the impaired cellular processes by A␤.
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